

MEDICAL ONCOLOGY**PAPER – II**

Time : 3 hours

MED.ONCO./D/17/17/II

Max. Marks : 100

Important instructions:

- Attempt all questions in order.
- Each question carries 10 marks.
- Read the question carefully and answer to the point neatly and legibly.
- Do not leave any blank pages between two answers.
- Indicate the question number correctly for the answer in the margin space.
- Answer all the parts of a single question together.
- Start the answer to a question on a fresh page or leave adequate space between two answers.
- Draw table/diagrams/flowcharts wherever appropriate.

Write short notes on:

1. Describe about breast cancer under following headings. 3+7
 - a. Her 2 neu gene testing: Immunohistochemistry versus FISH.
 - b. Use of Her-2 neu targeted therapy in neo-adjuvant, adjuvant and metastatic setting.
2.
 - a. List the investigation in a suspected case of chronic myeloproliferative disease (CMPD)
 - b. Molecular biology of Ph negative CMPD
 - c. Ruxolitinib: Indications and side effects3+3+4
3.
 - a. Lugano staging of non Hodgkin's lymphoma
 - b. Describe criteria for response assessment in lymphoma4+6
4.
 - a. Pathology of gastric carcinoma
 - b. Treatment both chemotherapy and targeted for unresectable gastric carcinoma4+6
5.
 - a. List various cytotoxic agents associated with severe emesis.
 - b. Prevention and treatment of chemotherapy induced nausea and vomiting with various agents.
 - c. Explain their mechanism of action and side effects.3+4+3
6.
 - a. Pathology of medulloblastoma.
 - b. Molecular classification of medulloblastoma
 - c. Staging of medulloblastoma and salient investigations for its staging.3+3+4

P.T.O.

MEDICAL ONCOLOGY**PAPER – II**

7. a. Role of check point inhibitors in non small cell lung cancer (NSCLS) 3+4+3
b. Algorithm for first time treatment of metastatic NSCLS
c. Role of ceritinib and alectinib in NSCLC with brain metastasis
8. a. Pathology and staging of prostate cancer. 5+2+3
b. What is androgen resistant prostate cancer?
c. Chemotherapy indications in prostate cancer with 'supporting indications'.
9. a. Pathology of Rhabdomyosarcoma. 4+3+3
b. Cytogenetic/ Translocation studies in sarcoma: mention tumours where it is useful in diagnosis
c. Huvos grading in osteosarcoma
10. a. Grading of pancreatic neuro-endocrine tumours. 3+4+3
b. Utility of nuclear medicine for diagnosis and treatment of neuroendocrine tumour.
c. Chemotherapy of neuroendocrine tumor.

www.FirstRanker.com